Cheng Andrew's Insider Trades & SAST Disclosures
Cheng Andrew's most recent trade in Akero Therapeutics Inc was a trade of 1,738 Common Stock done at an average price of $44.9 . Disclosure was reported to the exchange on March 12, 2025.
Add Superstar Alert
Note
This is a custom search result for pattern Cheng Andrew.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 44.88 per share. | 12 Mar 2025 | 1,738 | 654,324 (2%) | 0% | 44.9 | 78,001 | Common Stock |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 41.75 per share. | 10 Mar 2025 | 28,784 | 657,278 (2%) | 0% | 41.7 | 1,201,617 | Common Stock |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 42.31 per share. | 10 Mar 2025 | 1,216 | 656,062 (2%) | 0% | 42.3 | 51,453 | Common Stock |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 51.75 per share. | 10 Feb 2025 | 12,640 | 703,422 (2%) | 0% | 51.8 | 654,145 | Common Stock |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 53.67 per share. | 10 Feb 2025 | 9,972 | 687,011 (2%) | 0% | 53.7 | 535,157 | Common Stock |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 52.91 per share. | 10 Feb 2025 | 6,439 | 696,983 (2%) | 0% | 52.9 | 340,675 | Common Stock |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 54.55 per share. | 10 Feb 2025 | 749 | 686,262 (2%) | 0% | 54.5 | 40,855 | Common Stock |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 55.81 per share. | 10 Feb 2025 | 200 | 686,062 (2%) | 0% | 55.8 | 11,162 | Common Stock |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 54.56 per share. | 27 Jan 2025 | 24,242 | 721,820 (2%) | 0% | 54.6 | 1,322,644 | Common Stock |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 56.89 per share. | 27 Jan 2025 | 3,377 | 716,062 (2%) | 0% | 56.9 | 192,118 | Common Stock |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 55.53 per share. | 27 Jan 2025 | 2,381 | 719,439 (2%) | 0% | 55.5 | 132,217 | Common Stock |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2025 | 50,000 | 52,212 | - | - | Stock Option (Right to Buy) | |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.62 per share. | 23 Jan 2025 | 50,000 | 746,062 (2%) | 0% | 0.6 | 30,750 | Common Stock |
|
Akero Therapeutics Inc
|
Cheng Andrew | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2024 | 295,600 | 295,600 | - | - | Stock Option (Right to Buy) | |
|
Akero Therapeutics Inc
|
Cheng Andrew | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2024 | 98,500 | 696,062 (2%) | 0% | 0 | Common Stock | |
|
Akero Therapeutics Inc
|
Cheng Andrew | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 30.79 per share. | 10 Dec 2024 | 7,855 | 597,562 (2%) | 0% | 30.8 | 241,855 | Common Stock |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 32.09 per share. | 02 Dec 2024 | 25,000 | 605,417 (2%) | 0% | 32.1 | 802,250 | Common Stock |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.10 per share. | 02 Dec 2024 | 25,000 | 630,417 (2%) | 0% | 21.1 | 527,500 | Common Stock |
|
Akero Therapeutics Inc
|
Cheng Andrew | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 25,000 | 111,029 | - | - | Stock Option (Right to Buy) | |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.10 per share. | 01 Nov 2024 | 81,280 | 686,697 (2%) | 0% | 21.1 | 1,715,008 | Common Stock |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 81,280 | 163,115 | - | - | Stock Option (Right to Buy) | |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 31.47 per share. | 01 Nov 2024 | 81,280 | 605,417 (2%) | 0% | 31.5 | 2,558,044 | Common Stock |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 27,086 | 136,029 | - | - | Stock Option (Right to Buy) | |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 32.50 per share. | 01 Nov 2024 | 27,086 | 605,417 (2%) | 0% | 32.5 | 880,268 | Common Stock |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.10 per share. | 01 Nov 2024 | 27,086 | 632,503 (2%) | 0% | 21.1 | 571,515 | Common Stock |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.10 per share. | 16 Oct 2024 | 63,539 | 668,956 (2%) | 0% | 21.1 | 1,340,673 | Common Stock |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Oct 2024 | 63,539 | 93,709 | - | - | Stock Option (Righto Buy) | |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 31.53 per share. | 16 Oct 2024 | 63,313 | 605,643 (2%) | 0% | 31.5 | 1,996,069 | Common Stock |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.10 per share. | 16 Oct 2024 | 24,992 | 630,409 (2%) | 0% | 21.1 | 527,331 | Common Stock |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 31.14 per share. | 16 Oct 2024 | 24,992 | 605,417 (2%) | 0% | 31.1 | 778,151 | Common Stock |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Oct 2024 | 24,992 | 160,351 | - | - | Stock Option (Righto Buy) | |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.10 per share. | 16 Oct 2024 | 3,103 | 608,520 (2%) | 0% | 21.1 | 65,473 | Common Stock |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 31.12 per share. | 16 Oct 2024 | 3,103 | 605,417 (2%) | 0% | 31.1 | 96,559 | Common Stock |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Oct 2024 | 3,103 | 157,248 | - | - | Stock Option (Righto Buy) | |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 32.12 per share. | 16 Oct 2024 | 226 | 605,417 (2%) | 0% | 32.1 | 7,259 | Common Stock |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 26.18 per share. | 10 Sep 2024 | 1,738 | 605,417 (2%) | 0% | 26.2 | 45,501 | Common Stock |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.62 per share. | 16 Aug 2024 | 24,538 | 607,155 (2%) | 0% | 0.6 | 15,091 | Common Stock |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2024 | 24,538 | 0 | - | - | Stock Option (Right to Buy) | |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 19.94 per share. | 28 Jun 2024 | 1,064 | 582,617 (2%) | 0% | 19.9 | 21,217 | Common Stock |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 22.64 per share. | 11 Jun 2024 | 7,894 | 581,553 (2%) | 0% | 22.6 | 178,728 | Common Stock |
|
Vera Therapeutics Inc - Or...
|
Andrew Cheng | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2024 | 14,000 | 14,000 | - | - | Stock Option (right to buy) | |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 28.33 per share. | 13 Mar 2024 | 1,969 | 589,447 (2%) | 0% | 28.3 | 55,782 | Common Stock |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 04 Mar 2024 | 57,733 | 649,149 (2%) | 0% | 16 | 923,728 | Common Stock |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2024 | 57,733 | 10,000 | - | - | Stock Option (Right to Buy) | |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 31.40 per share. | 04 Mar 2024 | 35,827 | 630,589 (2%) | 0% | 31.4 | 1,124,975 | Common Stock |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.10 per share. | 04 Mar 2024 | 17,267 | 666,416 (2%) | 0% | 21.1 | 364,334 | Common Stock |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2024 | 17,267 | 244,395 | - | - | Stock Option (Right to Buy) | |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 34.63 per share. | 04 Mar 2024 | 14,680 | 599,525 (2%) | 0% | 34.6 | 508,373 | Common Stock |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 33.83 per share. | 04 Mar 2024 | 9,614 | 614,205 (2%) | 0% | 33.8 | 325,267 | Common Stock |
|
Akero Therapeutics Inc
|
Andrew Cheng | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 35.49 per share. | 04 Mar 2024 | 7,995 | 591,530 (2%) | 0% | 35.5 | 283,775 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges